PARP inhibitor + bevacizumab maintenance (HRD-positive)
In tumours with faulty DNA repair, adding olaparib to bevacizumab maintenance roughly doubled progression-free time and improved survival.
PAOLA-1: PFS 37.2 vs 17.7 months (HR 0.33) and 5-year OS 65.5% vs 48.4% in HRD-positive disease; no benefit in HRD-negative tumours. Approved 2020. The combination made HRD testing a routine first-line decision.
Pages like this
not linked directly; found by shared links- TrialDUO-O / ENGOT-ov46
Shares Bevacizumab, Olaparib, PARP, Ovarian cancer.
- IdeaA functional test for homologous recombination deficiency validated across laboratories
Shares Homologous recombination deficiency (HRD), Olaparib, PARP, Ovarian cancer.
- TrialPRIMA / ENGOT-OV26
Shares Homologous recombination deficiency (HRD), PARP, Ovarian cancer.
- TrialSOLO-1
Shares Olaparib, PARP, Ovarian cancer.
- TrialGOG-0218 & ICON7 (bevacizumab)
Shares Bevacizumab, VEGF / VEGFR, Ovarian cancer.
- PersonAmit M. Oza
Shares Olaparib, PARP, Ovarian cancer.
- InstitutionARCAGY-GINECO
Shares PAOLA-1 / ENGOT-ov25, Homologous recombination deficiency (HRD), Olaparib, Ovarian cancer.
- PersonAlan Ashworth
Shares Olaparib, PARP, Ovarian cancer.